Norgine receives positive CHMP opinion recommending approval of NPJ5008 (dantrolene sodium hemiheptahydrate) for the treatment of malignant hyperthermia

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Norgine-CHMP-NPJ5008

More Like This

PR Newswire associated0

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

PR Newswire associated0

Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome

PR Newswire associated0

Norgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

PR Newswire associated0

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.

PR Newswire associated0

Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology

PR Newswire associated0

Norgine strengthens rare disease portfolio with acquisition of Theravia

PR Newswire associated0

Norgine announces £23 million new investment as part of more than £50 million committed to expanding medicines manufacturing in Wales

PR Newswire associated0

Norgine Announces Appointment of New CEO Janneke van der Kamp